设为首页收藏本站
开启辅助访问
切换到窄版

 找回密码
 注册

QQ登录

只需一步,快速开始

搜索
查看: 549|回复: 0

使用一种靶向B细胞成熟抗原的双特异性抗体治疗多发性骨髓瘤

[复制链接]
发表于 2016-1-25 10:04:58 | 显示全部楼层 |阅读模式
An anti-B cell maturation antigen bispecific antibody for multiple myeloma.
The development of immunotherapies for multiple myeloma is critical to provide new treatment strategies to combat drug resistance. We report a bispecific antibody against B cell maturation antigen (BiFab-BCMA), which potently and specifically redirects T cells to lyse malignant multiple myeloma cells. BiFab-BCMA lysed target BCMA-positive cell lines up to 20-fold more potently than a CS1-targeting bispecific antibody (BiFab-CS1) developed in an analogous fashion. Further, BiFab-BCMA robustly activated T cells in vitro and mediated rapid tumor regression in an orthotopic xenograft model of multiple myeloma. The in vitro and in vivo activities of BiFab-BCMA are comparable to those of anti-BCMA chimeric antigen receptor T cell therapy (CAR-T-BCMA), for which two clinical trials have recently been initiated. A BCMA-targeted bispecific antibody presents a promising treatment option for multiple myeloma.
使用一种靶向B细胞成熟抗原的双特异性抗体治疗多发性骨髓瘤
多发性骨髓瘤的免疫疗法的发展是新的对抗耐药性治疗策略的关键。我们报导了一种靶向B细胞成熟抗原的双特异性抗体(BiFab-BCMA),能强有力地重定向T细胞杀伤恶性多发性骨髓瘤细胞。BiFab-BCMA裂解靶标BCMA阳性细胞的能力是同一种类似的双特异性抗体BiFab-CS1的20多倍。此外,BiFab-BCMA能够在体外强力的活化T细胞并且在多发性骨髓瘤原位移植瘤模型中强烈的介导肿瘤抑制。体内和体外的BiFab-BCMA的活性与CAR-T-BCMA相比,相差无几,这两个临床试验也已经开始了。一个靶向BCMA的双特异性抗体代表着一个对抗多发性骨髓瘤的有前景的治疗方案。
出自爱康得生物技术

您需要登录后才可以回帖 登录 | 注册

本版积分规则

QQ|申请友链|小黑屋|手机版|Archiver|生物信息学论坛 ( 蜀ICP备09031721号  

GMT+8, 2017-5-1 04:57 , Processed in 0.112240 second(s), 20 queries .

Powered by Discuz! X3

© 2001-2013 Comsenz Inc.

快速回复 返回顶部 返回列表